N. Bach

发表

Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.

N. Roehm, C. Román, J. Fleisch, 1999, The Journal of pharmacology and experimental therapeutics.

Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.

D. R. Berry, N. Chirgadze, D. Clawson, 1996, Journal of medicinal chemistry.

Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.

D. R. Berry, N. Chirgadze, D. Clawson, 1996 .

Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.

D. R. Berry, N. Chirgadze, D. Clawson, 1996, Journal of medicinal chemistry.

Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides.

D. R. Berry, N. Chirgadze, D. Clawson, 1996, Journal of medicinal chemistry.

Effects of (8beta)-8-[methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats.

J. Clemens, R. Fuller, H. Snoddy, 1979, Life sciences.

The discovery of LY293111, a novel, potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class.

W. Jackson, M. Sofia, S. Silbaugh, 1997, Advances in experimental medicine and biology.

Inhibition of prolactin secretion by ergolines.

J. Clemens, C. Shaar, E. Smalstig, 1974, Endocrinology.

Recombinant human secretory phospholipase A2 released thromboxane from guinea pig bronchoalveolar lavage cells: in vitro and ex vivo evaluation of a novel secretory phospholipase A2 inhibitor.

J. L. Bobbitt, W. Jackson, E. D. Mihelich, 1996, The Journal of pharmacology and experimental therapeutics.

Bicyclic and tricyclic ergoline partial structures. Rigid 3-(2-aminoethyl)pyrroles and 3- and 4-(2-aminoethyl)pyrazoles as dopamine agonists.

J. Clemens, N. D. Jones, J. Paschal, 1980, Journal of medicinal chemistry.

Synthesis of 2-azapodophyllotoxin

H. Pearce, N. Bach, T. L. Cramer, 1989 .

Nuclear magnetic resonance spectral analysis of the ergot alkaloids.

C. Chang, H. Floss, E. Wenkert, 1974, The Journal of organic chemistry.

The conversion of lysergic acid to the clavine alkaloids, penniclavine and elymoclavine, and to descarboxylysergic acid

N. Bach, E. Kornfeld, 1975 .

Activity of 6-methyl-8-substituted ergolines against the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma.

J. Clemens, N. Bach, M. J. Sweeney, 1975, Cancer research.

Dimerization of ergot derivatives

N. Bach, E. Kornfeld, 1973 .

NUCLEAR MAGNETIC RESONANCE SPECTRAL ANALYSIS OF THE ERGOT ALKALOIDS

E. Hagaman, H. Floss, E. Wenkert, 1974 .

Descarboxylysergic acid (9,10-didehydro-6-methylergoline).

D. A. Hall, N. Bach, E. Kornfeld, 1974, Journal of medicinal chemistry.

The synthesis of [2H], [3H], and [14C]‐labeled 8β‐[(methylthio)methyl]‐6‐propylergoline mesylate (pergolide mesylate), a potent, long‐acting dopamine agonist

W. J. Wheeler, N. Bach, D. Kau, 1990 .

Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2

J.-P. Wery, D. Clawson, R. Schevitz, 1995, Nature Structural Biology.

Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.

H L Pearce, W. T. Beck, A. Safa, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.

W. Jackson, J. S. Sawyer, P. Floreancig, 1995, Journal of medicinal chemistry.

Synthetic and Structure-Activity Studies on Acid-Substituted 2- Arylphenols: Discovery of 2-(2-Propyl-3-(3-(2-ethyl-4-(4-fluorophenyl)- 5-hydroxyphenoxy)propoxy)phenoxy)benzoic Acid, a High-Affinity Leukotriene B4 Receptor Antagonist.

W. Jackson, M. Sofia, S. Silbaugh, 1996 .

Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A2 inhibitors.

J. L. Bobbitt, E. D. Mihelich, J. Sharp, 1996, European journal of pharmacology.